ArticleBMC cardiovascular disorders2025
A case-control study of the interaction of the eNOS gene polymorphisms rs1799983 and rs1800780 with acute coronary syndrome (ACS) risk factors.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndothelial nitric oxide synthase (eNOS) gene polymorphisms may affect its enzymatic activity and nitric oxide (NO) production, which in turn interfere with endothelial function, regulate vascular tone, and participate in inflammatory responses. This ultimately affects the risk and prognosis of acute coronary syndrome (ACS). The aim of this study is to explore the association of eNOS gene polymorphisms with ACS risk factors.
methodsPatients who were hospitalized for coronary angiography in the First Affiliated Hospital of Xinjiang Medical University from January 2016 to December 2019 were selected. According to the appropriate inclusion and exclusion criteria. ACS and control groups were matched for general information such as gender, age, smoking, and alcohol consumption. 718 patients with ACS and 1008 controls were finally included. Genotyping was detected using the SNPscanTM Multiple SNP Typing Kit. The χ2 test was used to compare baseline information and gene model distribution between the ACS and control groups. Logistic regression was used to calculate the odds ratio (OR) and 95% confidence interval (95% CI).
resultsThis study included 718 patients with ACS and 1008 controls. The results of the analysis of the clinical baseline data after adjusting for confounders showed: age (OR = 1.025; 95%CI: 1.011–1.039; P < 0.001), gender (OR = 1.434; 95%CI: 1.012–2.032; P = 0.042), smoking (OR = 5.665; 95%CI: 3.954–8.117; P < 0.001), diabetes: (O R = 1.741;95%CI: 1.252–2.421,P = 0.001), NLR (OR = 1.387; 95%CI: 1.271–1.513; P < 0.001), PAR (OR = 1.269,95%CI: 1.177–1.369, P < 0.001), TyG (OR = 2.229; 95%CI. 1.847–2.689; P < 0.001), alcohol consumption (OR = 0.410; 95%CI: 0.292–0.577; P < 0.001), and the dominant model of the rs1799983 locus of the eNOS gene (TTvsGG + TG, OR = 3.157, 95%CI: 1.045–9.533, P = 0.042) were all significant influences on ACS.
conclusionACS interacted significantly with eNOS gene polymorphisms and was strongly associated with NLR, PAR, and TyG levels. Traditional risk factors were significantly different between the ACS and control groups. The dominant model of rs1799983 influences the development of ACS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.